Bionomics Expands Aussie Phase II Trials For Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Bionomics says it has added a dozen new sites for conducting Phase II trials of its BNC105 drug for treating mesothelioma, a lung cancer often caused by exposure to asbestos
You may also be interested in...
People On The Move: Appointments At Sanofi, Enzymatica And Bayer
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.
Trust, Innovation And Growth – Three Priorities For The Global Self-Care Industry In 2021
The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."
After Ups and Downs, Industry Attempts To Normalize In Q3
After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.
Need a specific report? 1000+ reports available
Buy Reports